* β-lactam antibiotics :l:
** carbapenems
*** spectrum
Gram±
*** TODO target
** cephalosporins
*** resistant strains :l:
**** MRSA
Methicillin Resistant S. aureus
**** ESBL
Extended spectrum b-lactamase producing strain
**** VRSA
Vancomycin Resistant S. aureus
**** VISA
Vancomycin intermediate S. aureus
**** CRE
Carbapenem resistant Enterobacteriaceae
**** VRE :ignore:
vancomycin resistant eterococci
*** organisms not covered by cephalosporins
mnemonic is LAME
- Listeria
- Atypicals
- MRSA (exception: Ceftaroline)
- Enterococci
*** 1st generation
**** indications
- most commonly used class in hospitals
- ineffective in treating meningitis
**** drugs :l:
***** Cefadroxil (PO)
***** Cefazolin
****** indication
surgical prophylaxis
***** Cephalexin (PO)
***** Cephalothin
***** Cephapirin 
***** Cephradin
**** spectrum
- Staphylococci (MSSA)
- Streptococci
  - GAS: S. pyogenes
  - Viridans group streptococci
  - S. pneumoniae
- Anaerobic cocci
  - Peptococci
  - peptostreptococci
- some E. Coli
- Klebsiella 
- Proteus
*** 2nd generation
**** true cephalosporins
***** spectrum
more Gram- exposure
***** indications
- sinusitis, otitis, LRT infections
- pneumon*
  - community acquired pneumonia
  - penicillin resistant pneumococci
- not effective against meningitis
**** cephamycins; cephalosporin-like
***** drugs
- cefotetan
- cefoxitin
***** spectrum
***** indications
***** counseling point
disulfiram-like reaction with alcohol
**** 3rd generation
***** drugs :l:
****** Ceftazidime
****** Cefoperazone
****** Ceftriaxone
****** cefotaxime
****** cefdinir
****** Ceftazidime + Avibactam
******* brand
Avycaz
**** 4th generation
***** drugs
Cefepime
***** spectrum
- Pseudomonads
- Enterobacteriaceae
- Haemophillus and Neisseria
**** 5th generation
***** drugs :l:
****** Ceftobiprole
****** Ceftaroline
****** Ceftolozane
****** Ceftolozane + Tazobactam
******* brand
Zerbaxa
***** Spectrum
MRSA
*** 3rd generation
*** 4th generation
*** spectrum
Gram±
** cephamycins
** monobactams
** penicillins
*** aminopenicillins
*** Pen G, V
*** Antipseudomonal
*** Combination with β-lactamase inhibitor
* cell wall inhibitors
** glycopeptide antibiotics
*** spectrum
Gram+
*** drugs
**** vancomycin
***** spectrum
- narrow spectrum
- Gram+
- MRSA
- penicillin-resistant S. pneumoniae
- susceptible Enterococci
***** indication
- IV used for nosocomial MRSA
- Clostridium dificile colitis
- Streptococcus pneumoniae
***** resistance
- in Enterococci
- vancomycin cannot bind to target site because of a change in AA sequence
***** MOA
- cell wall synthesis inhibitor
- blocks transpeptidase binding; peptidoglycan cross-linking
**** telavancin
**** dalbavancin
**** oritavancin
** other cell wall or memebrane active agents
*** lipopeptides
**** daptomycin
cyclic lipopetide antibiotic
***** spectrum
- aerobic Gram+ bacteria
- /not/ for Gram- bacteria
- reserve for resistant strains
  - MRSA
  - penicillin-resistant S. pneumoniae
  - vancomycin-resistant enterococi and S. aureus
- Enterococcus
***** ADRs
- monitor creatine
- monitor phosphokinase
- do not use for pneumonia
***** brand
Cubicin
***** MOA
- lipophillic decanoyl side chain inserts into cell membrane
- bactericidal
- blocks DNA, RNA, and protein biosynthesis
***** indications
- endovascular infections
***** formulation
IV; expensive
*** fosfomycin
**** MOA
inhibits synthesis of N-acetylmuramic acid
**** spectrum
- Gram±
- acts synergistically with
  - β-lactam antibiotics
  - aminoglycosides
  - fluoroquinolones
*** bacitracin
**** spectrum
Gram+
**** MOA
inhibits dephosphorylation in recycling of bacterophenol, the lipid carrier
**** TODO indication
*** cycloserine
**** spectrum
- broad
- M. tuberculosis
- Gram±
- many Gram- bacteria
  - E. coli
  - Enterococci
  - S. aureus
  - Chlamydia
**** MOA
inhibits incorporation of D-alanine into the peptioglycan pentapeptide
**** indication
tuberculosis caused by M. tuberculosis resistant to first line agents
**** adverse effects
neuropsyciatric symptoms
*** polymyxins
**** spectrum
Gram-
**** MOA
as a cationic detergent-like, it binds to lipid A portion of endotoxin, disrupts the outer and inner membrane
* sulfonamides & trimethoprim
** sulfonamides
*** MOA
- folic acid synthesis inhibitors
- bacteriostatic
- inhibits /dihydropteroate synthase/—responsible for converting PABA → dihydropteroic acid
*** MOR (mechanism of resistance)
- overproduction of PABA
- impaired permeability of bacteria to sulfonamide
- folic dihydropteroate synthase  with low affinity to sulfonamides
*** spectrum
broad
*** drugs
**** combinations :l:
***** trimethroprim-sulfamethoxoazole
****** brand
- Bactrim
- Septra
****** indications
******* Bhave
- P. jiroveci pneumonia
- Shigellosis
- systemic salmonella infections
- prostatitis
- lower urinary tract infections, empirical therapy for
******* Mody
- uncomplicated UTI
- community acquired MRSA
- pneumocystis pnemumonia (PCP)
  - caused by P. jiroveci
  - prophylaxis treatment in implant or HIV patients
- /Toxoplasma gondii/
***** pyrimethamine + sulfadiazine
***** pyrimethamine + sulfadoxine
****** brand
Fansidar
****** indications
- leishmaniasis
- toxoplasmosis
- falciparum marlaria
*** adverse reactions
- dermatological disturbances
  - Stevens-Johnson syndrome
- urinary tract disturbances
- hematopoietic disturbances
*** spectrum
**** effective
- Gram±
- Nocardia, Chlamydia trachomatis, and some protozoa
- Enteric bacteria: E. coli, Klebsiella, Salmonella, Shigella, and Enterobacter 
**** not effective
- Rickettsiae: sulfonamides stimulate their growth
- Anaerobes: poor activity 
- P. aeruginosa is intrinsically resistant
- Enterococci 
*** SAR
**** pKa
sulfanilamide = 10.4
PABA = 6.5
** pyrimidines
*** MOR
- reduced cell permeability
- overproduction of dihydrofolate reductase
- production of an altered reductase with reduced drug binding
*** drugs :l:
**** trimethoprim
***** target
dihydrofolate reductase (???)
***** indication, oral
- only for lower urinary tract infections
- patients with sulfonamide allergy
**** pyrimethamine
*** adverse effects
- antifolate effects
*** contraindications
- AIDS
- pneumocystis pneumonia
* fluoroquinolones
** MOA
- blocks bacterial DNA synthesis
- inhibits bacterial topoisomerase II (DNA gyrase)
- inhibits topoisomerase IV
** classes :l:
*** quinolones
**** naming
- *floxacin: fluorinated derivatives
- nalidixic acid
**** group 1
***** drugs
norfloxacin
**** group 2
***** drugs
- Ciprofloxacin
- enoxacin
- levofloxacin
- lomefloxacin
- ofloxacin
- pefloxacin 
**** group 3
***** drugs
- Gatifloxacin
- gemifloxacin
- moxifloxacin
**** delafloxacin
***** brand
Baxxdela
***** spectrum
- MSSA and MRSA
- Streptococci species
- Enterococcus faecalis
- GNRs: 
  - E. coli, 
  - Enterobater cloacae
  - K. pneumonia
  - P. aeruginosa 
**** ozenoxacin
***** brands
- Ozaenex
- Xepi
***** spectrum
activity against bacteria that have shown resistance to other quinolones
***** indication
impetigo
***** formulation
use 1% topical cream
**** indications
- anthrax
- urinary tract infections
* aminoglycosides
** MOA
- ribosomal protein synthesis inhibitor
- irreversible binding to 30S ribosomal subunit
- bactericidal
** MOR
- transferase enzyme inactivates the aminoglycoside
- aminoglycoside unable to enter cell
- mutation alters or deletes receptor protein on the 30S ribosomal subunit
** PK
*** formulation
- not used orally
- IM or IV
*** postantibiotic effect
- antibacterial activity persists long after the drug is present in measurable amounts
- better efficacy seen with a single large dose over multiple smaller doses
- once daily dosing is just as effective and safe as multiple smaller doses
** indications
- Gram- enteric bacteria
- sepsis
- combination with β-lactam antibiotics
** adverse effects
- ototoxicity
- nephrotoxicity
- respiratory paralysis
** combination with beta-lactam antibiotic
- to extend coverage to gram+ pathogens 
- to take advantage of the synergism between these two classes of drugs
- Enterococcal endocarditis 
- to shorten duration of therapy for
  - Viridans streptococcal infections
  - staphylococcal endocarditis

** drugs :l:
*** streptomycin
*** gentamicin
*** plazomicin
**** brand
ZEMDRI
*** tobramycin
*** amikacin
*** neomycin
*** spectinomycin
* tetracyclines, glycylcyclines, macrolides, ketolides
** tetracyclines
*** MOA
- reversibly inhibit bacterial protein synthesis at 30S ribosomal subunit
- bacteriostatic
*** spectrum
- broad
  - G±
  - anaerobes
  - atypicals
*** resistance
**** intrinsicially resistant species
- P. aeruginosa
- Proteus spp.
*** formulation
oral; except for:
- tigecycline
- streptogramins
*** drugs :l:
**** Minocycline
***** brand
Minocin
**** Doxycycline
***** brand
Monodox
**** Oxytetracycline
**** Omadacycline 
***** indications
- pneumonia, CA
- skin infections
- resistant strains
**** Eravacycline
***** indications
- cIAI
- cUTI
*** PK
**** distribution
high concentrations in tears and saliva, making it useful for eradicating the meningococcal carrier state
**** absorption
***** interference
- food
- antacids
- dairy products
***** portion never leaves (???) gut
superinfections
*** indications
- anthrax
- atypical pneumonia
- Rocky mountain spotted fever
- nephrogenic diabetes insipidus (off label)
*** adverse effects
- onycholysis
- photosensitivity
- renal toxicity
- hepatotoxicity
** glycylcyclines
*** drugs :l:
**** Tigecycline
***** brand
Tigacyl
**** Eravacycline
** macrolides
*** spectrum
- Gram±
- atypical
*** MOA
inhibits bacterial protein synthesis by inhibiting the 50S ribosomal RNA subunit
*** MOR
- plasmid-encoded
*** drugs :l:
**** erythromycin
**** clarithromycin
***** brand
Biaxin
***** advantages compared to erythromycin
- lower GI intolerance
- less frequent dosing
- activity against Mycobacteria
**** azithromycin
***** brand
Zithromax
** ketolides
*** drugs :l:
**** telithromycin
***** brand
Ketek
** misc :l:
*** TODO clindamycin
**** indications
- MRSA
**** spectrum
- G+ aerobes/anaerobes
- bacteroides
- MRSA
**** MOA
*** chloramphenicol
*** streptogramins
**** drugs :l:
***** Quinupristin-Dalfopristin
****** brand
Synercid
****** spectrum
- narrow
- Gram+ cocci
**** PK
- hepatic insufficiency
- CYP3A4
*** oxazolidinones :l:
**** linezolid
- reserved for multidrug-resistant Gram-(+) bacteria
- very expensive drug
- vancymycin-resistant E. faecium infections
- pneumonia
  - nosocomial
  - community acquired
***** indication
multidrug-resistant Gram+ bacteria
* metronidazole, mupirocin, urinary antiseptics
** metronidazole
*** brands
- Flagyl
- Metro
*** indication
- anaerobes
- C. difficile
- vaginitis
** fidaxomicin
*** brands
- Dificid
- Dificilir
** Mupirocin
*** brand
Bactroban
** Nitrofurantoin
*** brand
Macrobid
*** contraindication
CrCl <60 mL/min
* renal dose adjustment
** requiring :l:
** not requiring :l:
*** streptogramins
* bugs -> drugs
** Predominantly Gram+ spectrum
- Bacitracin
- Clindamycin
- Daptomycin
- Linezolid
- Mupirocin
- Penicillin G
- Streptogramins (Q/D)
- Vancomycin
** Predominantly Gram- spectrum
- Astreonam
- polymyxins
** Both Gram + and Gram - spectrum
- aminoglycoside+b-lactam combinations
- carbapenems
- Cephalosporins
- chloramphenicol
- cycloserine
- fluoroquinolones
- fosfomycin
- ketolides
- macrolides
- Nitrofurantoin
- spectinomycin
- sulfonamides
- tetracyclines
** Anaerobes
- Metronidazole
- Clindamycin
- carbapenems
- 1st gen cephalosporins (anaerobic cocci),cephamycins
- ceftizoxime (3rd gen)
- oral Vanco
- fidaxomicin
** Atypicals
- 3rd gen cephalosporin (Borrelia)
- ciprofloxacin
- Doxycycline (Rickettsia, chlamydia)
- macrolides
- ketolide
- sulfonamides (Chlamydia but not rickettsia)
- Penicillin (T. pallidum)
** Intracellular
- Fluoroquinolones (legionella)
** Enterics
- cefepime (Enterobacter)
- cefclidine
- sulfonamides
- Fluoroquinolones
- aminoglycosides
** MSSA/MSSE
- Nafcillin
- Cephalosporins
- Streptogramins (Q/D)
** MRSA (CA and HA)
- Bactrim
- Ceftaroline (5th gen)
- vancomycin
- daptomycin Clindamycin
- tetracycline
- Streptogramins (Q/D)
- Mupirocin
- Linezolid
- Tigecycline
** VISA
- Dalbavancin
- Linezolid
- Q/D
- Tigecycline
- daptomycin
** Susceptible Enterococci
- 5th gen cephalosporins
- Vancomycin
- Linezolid
** VRE
- Daptomycin
- Streptogramins (Q/D)
- linezolid
** P. aeruginosa (inherently resistant to sulfonamides, tetracycline, nitrofurantoin)
- Antipseudomonal piperacillin
- ceftazidime
- cefepime
- carbapenems
- ciprofloxacin
- gentamycin
- Amikacin
*** Combos
- Zosyn®
- Timentin®
- Avicaz®
- Zerbaxa®
** C. difficile
- Vancomycin (oral)
- Metronidazole
- Fidaxomicin
** ESBL producing bacteria  
- 5th gen cephalosporins in combination with b-lactamase inhibitors
- carbapenems
** CRE (Carbapenem resistant Enterobacteriaceae)
- Ceftolozane + Tazobactam
- Ceftazidime + Avibactam
** H. influenzae
- Cefotaxime
- ceftriaxone
- Azithromycin
- fluoroquinolones
